Eli Lilly And The Alzheimer's Dilemma (Rating Upgrade) [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
Approval of donanemab could have a modestly positive impact on LLY stock, while denial could lead to a substantial (but not disastrous) drop. Donanemab appears to have little effect as a whole on non-APOE4 carriers, African Americans, and Hispanics. Alzheimer's disease appears to be primarily driven by the nitro-oxidant peroxynitrite rather than amyloid. Anti-peroxynitrite rather than anti-amyloid treatments are likely to be more successful. The Food and Drug Administration's approval of Eli Lilly's ( NYSE: LLY ) anti-amyloid antibody drug donanemab was once considered a slam dunk ( previous analysis ). But now, the FDA is convening an advisory panel to weigh in on the drug. This may just be a blip for Eli Lilly, or alternatively, concerns over donanemab's safety and efficacy could potentially lead to its rejection. Perhaps, the FDA is having approval remorse after its earlier thumbs up for Biogen ( BIIB ) and Eisai's ( OTCPK:ESALF ) Aduhelm (accelerated) and Leqembi (full).
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Analyst unveils Amgen stock price target after weight-loss drug data [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk To Slash Prices On Buzzy Drugs Ozempic and Wegovy [Yahoo! Finance]Yahoo! Finance
- 25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says [FOX Business Network]FOX Business Network
- Here Comes Obesity Drug Competition: Amgen Shares Soar On "Very Encouraging" Clinical Trial Update [zero hedge]zero hedge
- How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand' for weight-loss drugs [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 5/3/24 - Form SD
- 4/30/24 - Form 10-Q
- 4/30/24 - Form 8-K
- LLY's page on the SEC website